Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial
01/12/2026 11:58 AM • Pfizer announced positive Phase 3 BREAKWATER trial data showing its Braftovi combination therapy (with cetuximab and FOLFIRI) demonstrated a 64.4% confirmed objective response rate in BRAF V600E-mutant metastatic colorectal cancer patients, significantly outperforming standard-of-care treatment (39.2%). The drug received accelerated FDA approval in December 2024, with continued approval contingent on verification of clinical benefit.
PFE - Pfizer's Braftovi combination therapy demonstrated clinically meaningful and statistically significant improvements in tumor response rates (64.4% vs 39.2%) compared to standard treatment, with 57.4% of patients achieving responses lasting 6+ months. This strong efficacy data supports the drug's accelerated FDA approval and validates the treatment approach for BRAF V600E-mutant colorectal cancer.
Investing.com • Sam Quirke